Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 10/20 | 0.39 |
| ▸ | THRB | P10828 | 10/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.38 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140925 | 0.80 | THRA (0.45) | THRATHRB | |
| SCHEMBL5072132 | 0.78 | NT5E (0.35) | THRATHRB | |
| SCHEMBL5072134 | 0.78 | ESR1 (0.38) | THRATHRB | |
| SCHEMBL3140495 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2THRATHRBPPARGPPARA | |
| SCHEMBL3141333 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2 | |
| SCHEMBL3140799 | 0.71 | THRA (0.42) | THRATHRB | |
| SCHEMBL3140938 | 0.70 | THRA (0.46) | THRATHRB | |
| SCHEMBL15200586 | 0.69 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL5072138 | 0.69 | L3MBTL1 (0.38) | THRATHRB | |
| SCHEMBL5072131 | 0.69 | L3MBTL1 (0.38) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | SMN1; SMN2 4757/4885THRA 4/4885THRB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.